We are live on ! Find out more
MBRX icon

Moleculin Biotech
MBRX

22 hedge funds and large institutions have $2.91M invested in Moleculin Biotech in 2023 Q1 according to their latest regulatory filings, with 4 funds opening new positions, 6 increasing their positions, 1 reducing their positions, and 4 closing their positions.

New
Increased
Maintained
Reduced
Closed

500% more repeat investments, than reductions

Existing positions increased: 6 | Existing positions reduced: 1

0% more funds holding

Funds holding: 22 → 22 (0)

0% more ownership

Funds ownership: 0.03% → 0.03% (+0%)

0% more first-time investments, than exits

New positions opened: 4 | Existing positions closed: 4

8% less capital invested

Capital invested by funds: $3.17M → $2.91M (-$266K)

Holders
22
Holders Change
–
Holders Change %
0%
% of All Funds
0.35%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
4
Increased
6
Reduced
1
Closed
4
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
Squarepoint
Squarepoint
New York
+$28K
2
HF
HRT Financial
New York
+$18.4K
3
Citadel Advisors
Citadel Advisors
Florida
+$18K
4
TSS
Two Sigma Securities
New York
+$15.8K
5
Renaissance Technologies
Renaissance Technologies
New York
+$14.5K

Top Sellers

Rank Fund Capital Flow
1
Charles Schwab
Charles Schwab
California
-$38.8K
2
SCM
Sio Capital Management
New York
-$30.2K
3
UBS Group
UBS Group
Switzerland
-$11.9K
4
Rockefeller Capital Management
Rockefeller Capital Management
New York
-$1K
5
CA
Clearstead Advisors
Ohio
-$636
Name Holding Trade Value Shares
Change 		Change in
Stake
Vanguard Group
1
Vanguard Group
Pennsylvania
$1.04M – – –
SCM
2
Sio Capital Management
New York
$971K -$30.2K -69 -2%
BlackRock
3
BlackRock
New York
$248K +$2.19K +5 +0.7%
Geode Capital Management
4
Geode Capital Management
Massachusetts
$237K – – –
Renaissance Technologies
5
Renaissance Technologies
New York
$91K +$14.5K +33 +15%
State Street
6
State Street
Massachusetts
$68.5K – – –
SPC
7
Sigma Planning Corp
Michigan
$55.2K – – –
Northern Trust
8
Northern Trust
Illinois
$51.5K +$8.32K +19 +15%
Citadel Advisors
9
Citadel Advisors
Florida
$30.6K +$18K +41 +93%
Squarepoint
10
Squarepoint
New York
$23K +$28K +64 New
VF
11
Virtu Financial
New York
$16K +$3.07K +7 +19%
HF
12
HRT Financial
New York
$15K +$18.4K +42 New
TSS
13
Two Sigma Securities
New York
$13K +$15.8K +36 New
JE
14
JMAC Enterprises
Pennsylvania
$12.6K – – –
TRCT
15
Tower Research Capital (TRC)
New York
$12K +$8.32K +19 +136%
Susquehanna International Group
16
Susquehanna International Group
Pennsylvania
$10.7K +$13.1K +30 New
Bank of America
17
Bank of America
North Carolina
$6.48K – – –
Morgan Stanley
18
Morgan Stanley
New York
$6.08K – – –
Osaic Holdings
19
Osaic Holdings
Arizona
$930 – – –
CFO
20
CVA Family Office
Colorado
$480 – – –
NSIM
21
North Star Investment Management
Illinois
$240 – – –
Wells Fargo
22
Wells Fargo
California
$190 – – –
Fidelity Investments
23
Fidelity Investments
Massachusetts
$2 – – –
Charles Schwab
24
Charles Schwab
California
– -$38.8K -98 Closed
UBS Group
25
UBS Group
Switzerland
– -$11.9K -30 Closed
1
2

MBRX Hedge Fund Activity: Q1 2023 in Review

22 of the 6,276 institutional investors tracked by Wall St. Rank reported a position in Moleculin Biotech (MBRX) for Q1 2023, worth a combined $2.91M — down 8.4% from $3.17M a quarter earlier.

Fund positioning in MBRX was balanced in Q1 2023: 4 funds opened new positions, 4 closed out, 6 added to existing stakes and 1 trimmed.

The largest buyer was Squarepoint, opening a new position worth an estimated $28K. The largest seller was Charles Schwab, exiting entirely with an estimated $38.8K sold.

  • 22 institutional investors held Moleculin Biotech (MBRX) as of Q1 2023, unchanged from Q4 2022.
  • Funds reported $2.91M of Moleculin Biotech stock for Q1 2023, down 8.4% quarter-over-quarter.
  • 4 funds opened new Moleculin Biotech positions in Q1 2023 and 4 closed out, a net change of 0 holders.
  • The largest Moleculin Biotech buyer in Q1 2023 was Squarepoint, an estimated $28K added.
  • The largest Moleculin Biotech seller in Q1 2023 was Charles Schwab, an estimated $38.8K sold.

Based on aggregated 13F filings for Q1 2023.